Case Report

International Journal of Hematology

, 81:433

First online:

Rituximab Provided Long-Term Remission in a Patient with Refractory Relapsing Thrombotic Thrombocytopenic Purpura

  • Satoru KosugiAffiliated withDepartment of Internal Medicine, Toyonaka Municipal Hospital Email author 
  • , Masanori MatsumotoAffiliated withDepartment of Blood Transfusion Medicine, Nara Medical University
  • , Yasushi OhtaniAffiliated withDepartment of Internal Medicine, Toyonaka Municipal Hospital
  • , Hironori TakeAffiliated withDepartment of Internal Medicine, Toyonaka Municipal Hospital
  • , Hiromichi IshizashiAffiliated withDepartment of Blood Transfusion Medicine, Nara Medical University
  • , Yoshihiro FujimuraAffiliated withDepartment of Blood Transfusion Medicine, Nara Medical University
  • , Jun KuyamaAffiliated withDepartment of Internal Medicine, Toyonaka Municipal Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

We describe a 69-year-old man with refractory relapsing thrombotic thrombocytopenic purpura (TTP) successfully treated with rituximab. The patient had once been successfully treated with plasmapheresis and vincristine, but he had relapsed after a short period. Although plasmapheresis, vincristine, and splenectomy could not achieve a consistent elevation of the platelet count, rituximab administration provided sustained remission for more than 7 months. Rituximab should be considered as a therapeutic alternative for refractory TTP.

Key words

Thrombotic thrombocytopenic purpura (TTP) Rituximab von Willebrand factor-cleaving protease (VWF-CP) Anti-ADAMTS13 autoantibody